Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 3

Tramadol extended-release in the management of chronic pain

Authors Bill McCarberg

Published 15 July 2007 Volume 2007:3(3) Pages 401—410

Bill McCarberg

Director of the Chronic Pain Management Program, Kaiser Permanente, San Diego, CA, USA

Abstract: Chronic, noncancer pain such as that associated with osteoarthritis of the hip and knee is typically managed according to American College of Rheumatology guidelines. Patients unresponsive to first-line treatment with acetaminophen receive nonsteroidal antiinflammatory drugs (NSAIDs), including cyclooxygenase-2 (COX-2) inhibitors. However, many patients may have chronic pain that is refractory to these agents, or they may be at risk for the gastrointestinal, renal, and cardiovascular complications associated with their use. Tramadol, a mild opioid agonist and norepinephrine and serotonin reuptake inhibitor, is recommended by current guidelines for the treatment of moderate to moderately severe pain in patients who have not responded to previous oral therapy, or in patients who have contraindications to COX-2 inhibitors and nonselective NSAIDs. An extended-release (ER) formulation of tramadol was approved by the US Food and Drug Administration in September 2005. In contrast with immediate-release (IR) tramadol, this ER formulation allows once-daily dosing, providing around-the-clock analgesia. In clinical studies, tramadol ER has demonstrated a lower incidence of adverse events than that reported for IR tramadol. Unlike nonselective NSAIDs and COX-2 inhibitors, tramadol ER is not associated with gastrointestinal, renal, or cardiovascular complications. Although tramadol is an opioid agonist, significant abuse has not been demonstrated after long-term therapy. It is concluded that tramadol ER has an efficacy and safety profile that warrants its early use for the management of chronic pain, either alone or in conjunction with nonselective NSAIDs and COX-2 inhibitors.

Keywords: chronic pain, COX-2 inhibitor, NSAID, opioid, tramadol

Download Article [PDF] 

Readers of this article also read:

Developments in the management of autosomal dominant polycystic kidney disease

Amirali Masoumi, Berenice Reed-Gitomer, Catherine Kelleher, Mir Reza Bekheirnia, Robert W Schrier

Therapeutics and Clinical Risk Management 2008, 4:393-407

Published Date: 11 April 2008

Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas

Daniela A Bota, Annick Desjardins, Jennifer A Quinn, Mary L Affronti, Henry S Friedman

Therapeutics and Clinical Risk Management 2007, 3:707-715

Published Date: 15 November 2007

Chronic non-cancer pain: Focus on once-daily tramadol formulations

Flaminia Coluzzi, Consalvo Mattia

Therapeutics and Clinical Risk Management 2007, 3:819-829

Published Date: 15 November 2007

The renaissance of fixed dose combinations: Combivir

Simon D Portsmouth, Christopher J Scott

Therapeutics and Clinical Risk Management 2007, 3:579-583

Published Date: 15 September 2007

Creating diagnostic scores using data-adaptive regression: An application to prediction of 30-day mortality among stroke victims in a rural hospital in India

Merrill D Birkner, SP Kalantri, Vaishali Solao, Priya Badam, Rajnish Joshi, Ashish Goel, Madhukar Pai, Alan E Hubbard

Therapeutics and Clinical Risk Management 2007, 3:475-484

Published Date: 15 July 2007

Acute migraine: Current treatment and emerging therapies

Arun A Kalra, Debra Elliott

Therapeutics and Clinical Risk Management 2007, 3:449-459

Published Date: 15 July 2007

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy

Shimon Lecht, Simon Haroutiunian, Amnon Hoffman, Philip Lazarovici

Therapeutics and Clinical Risk Management 2007, 3:467-474

Published Date: 15 July 2007

Recombinant human epoetin beta in the treatment of renal anemia

Francesco Locatelli, Pietro Pozzoni, Lucia Del Vecchio

Therapeutics and Clinical Risk Management 2007, 3:433-439

Published Date: 15 July 2007

A review of rabeprazole in the treatment of acid-related diseases

Fabio Pace, Stefano Pallotta, Stefania Casalini, Gabriele Bianchi Porro

Therapeutics and Clinical Risk Management 2007, 3:363-379

Published Date: 15 July 2007